✦ LIBER ✦

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer

✍ Scribed by Chia-Chi Lin; Chih-Hsin Yang

Book ID: 107384345
Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 156 KB
Volume: 4
Category: Article
ISSN: 1776-2596
DOI: 10.1007/s11523-009-0104-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Significance of pretreatment comorbiditi

Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor

✍ Kaoru Irisa; Katsuhiro Masago; Yosuke Togashi; Shiro Fujita; Yukimasa Hatachi; A 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 294 KB

Trying to compose the puzzle with all th

Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

✍ Massimo Di Maio; Cesare Gridelli; Nicola Normanno; Francesco Perrone; Fortunato 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB

## Abstract Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown promising activity in patients with non‐small cell lung cancer (NSCLC). Gefitinib has been the first of these drugs to be licensed for third‐line treatment of advanced NSCLC patients. Mor

Epidermal growth factor receptor tyrosin

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues

✍ K. Bencardino; M. Manzoni; S. Delfanti; A. Riccardi; M. Danova; G. R. Corazza 📂 Article 📅 2007 🏛 Springer Milan 🌐 English ⚖ 117 KB

Epidermal growth factor receptor mutatio

Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer : Impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors

✍ Victor Cohen; Jason S. Agulnik; Celina Ang; Goulnar Kasymjanova; Gerald Batist; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 1 views

## Abstract ## BACKGROUND: Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to EGFR‐tyrosine kinase inhibitors (EGFR‐TKI) in patients with nonsmall cell lung cancer (NSCLC). ## METHODS: The authors tested the possibility that nucleoti

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

The impact of epidermal growth factor re

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

✍ Shuji Ichihara; Shinichi Toyooka; Yoshiro Fujiwara; Katsuyuki Hotta; Hisayuki Sh 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 403 KB 👁 2 views

## Abstract We investigated the relationships between genetic factors and clinical outcome in Japanese non‐small‐cell lung cancer (NSCLC) patients treated with gefitinib. Ninety‐eight NSCLC patients who had been treated with gefitinib, were screened for mutations in epidermal growth factor receptor